Myo-inositol Versus Metformin Administration in Post-menopausal Women With Metabolic Syndrome
Status:
Unknown status
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
Myo-Inositol is classified as a member of the vitamin B complex. It is a constituent of
living cells and is widespread in many food. It is involved in a number of biological
processes, including insulin signal transduction, resulting in modulating insulin
sensitivity. One hundred post-menopausal women from 50 to 60 years old, affected by metabolic
syndrome (criteria are described in NIH ATP III) will be randomized into two groups: 50
treated with myo-inositol 2 g twice per day and fifty treated with metformin for six months.
Metformin is the drug usually used in diabetic and pre-diabetic conditions, as metabolic
syndrome. The investigators hypothesize that the administration of myo-inositol would improve
the insulin-receptor activity in these women, reducing insulin resistance as well as
metformin.
OUTCOME MEASURE: HOMA-IR, blood pressure level, serum triglycerides and cholesterol, BMI and
waist circumference